Marina Biotech, well known for its developmental and innovative projects dealing with nucleic acid-based drugs, has announced the initiation of phase 1 clinical trials of MRX34 by its licensee, Mirna Therapeutics.
http://bionews-tx.com/news/2013/05/15/marina-biotech-licensee-mirna-therapeutics-reports-initiation-of-cprit-funded-phase-1-clinical-trial-of-anticancer-drug-mrx34/
No comments:
Post a Comment